<![CDATA[subtype and histological grade, both of which influence prognosis and therapeutic strategy. Although molecular classification using immunohistochemistry has become a standard component of breast cancer management, data regarding its correlation with histological grade in secondary healthcare facilities remain limited. This study aimed to analyze the relationship between molecular subtypes and histological grade of Nottingham breast carcinoma at dr. H. Jusuf SK Regional General Hospital. This retrospective analytical cross-sectional study included breast carcinoma patients diagnosed between January 2023 and September 2025. Only cases with complete immunohistochemical data (ER, PR, HER2, and Ki-67) were included in the analysis. Molecular subtypes were classified as Luminal A, Luminal B, HER2-enriched, and Triple-negative, while histological grading was determined using the Nottingham Histologic Score system (Grade I–III). The association between molecular subtype and histological grade was analyzed using Fisher’s Exact test, with statistical significance set at p < 0.05. A total of 51 patients met the inclusion criteria. Luminal B was the most frequent subtype (39.2%), followed by Luminal A (27.5%), HER2-enriched (25.5%), and Triple-negative (7.8%). Grade III tumors accounted for 51.0% of cases. HER2-enriched (69.2%) and Triple-negative (75.0%) subtypes were predominantly associated with Grade III tumors, whereas Luminal A tumors were more frequently associated with Grade II (57.1%) and lower-grade tumors. Statistical analysis demonstrated a significant association between molecular subtype and histological grade (Fisher’s Exact test, p < 0.05). These findings indicate a statistically significant relationship between molecular subtype and histological grade in Nottingham breast carcinoma. More aggressive molecular subtypes, particularly HER2-enriched and Triple-negative, are strongly associated with higher histological grade. This result highlights the biological concordance between molecular behavior and tumor differentiation and underscores the importance of comprehensive immunohistochemical evaluation in breast cancer management.]]>
Copyrights © 2026
